Physician profile
Ubong E Udofia
NPI 1760745889
$406,523.16
in general payments reported to CMS, 2019-2025
27 companies · $95K in 2025
The $95K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $61K · 2022: $81K · 2023: $69K · 2024: $100K · 2025: $95K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $196K · Food and Beverage: $26K · Consulting Fee: $24K · Travel and Lodging: $14K · Honoraria: $4,250 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $196,199.00 |
| Food and Beverage | $26,236.25 |
| Consulting Fee | $24,100.50 |
| Travel and Lodging | $13,504.79 |
| Honoraria | $4,250.00 |
| Education | $179.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $248,106.62 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $64,879.06 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $50,448.95 | 2021-2025 | |
| Axsome Therapeutics, INC. | $15,729.75 | 2022-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $12,334.87 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $7,080.06 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,729.36 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,406.02 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| E.R. Squibb & Sons, L.L.C. | $684.67 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $661.64 | 2021-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $660.48 | 2023-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $648.01 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $439.31 | 2022-2025 | Azstarys |
| Almatica Pharma LLC | $401.84 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Sunovion Pharmaceuticals INC. | $326.64 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $303.40 | 2021-2025 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $281.01 | 2021-2025 | Trintellix |
| Janssen Scientific Affairs, LLC | $111.40 | 2025 | |
| Avanir Pharmaceuticals, INC. | $73.08 | 2021-2022 | |
| Indivior INC. | $54.55 | 2024 | Perseris |
| Tris Pharma INC | $49.37 | 2022-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $28.08 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $27.48 | 2021-2023 | Belsomra |
| Braeburn INC. | $15.54 | 2025 | Brixadi |
| Ironshore Pharmaceuticals INC. | $14.15 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.00 | 2021 | |
| Noven Therapeutics, LLC | $13.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ubong Udofia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.